Birgit Schultes

Birgit Schultes oversees all platform and pipeline research activities across in vivo and ex vivo areas as Intellia’s chief scientific officer. With over two decades’ experience in the biotechnology and pharmaceutical industry, Birgit brings deep immunology and cell therapy expertise to Intellia. She manages a multidisciplinary team focused on ex vivo applications of CRISPR/Cas9 to generate novel cell therapies for oncology and autoimmune indications. Prior to joining Intellia, Birgit served as senior director, In Vivo and Exploratory Immunology, at Unum Therapeutics (now Cogent Biosciences, Inc.), where she was responsible for its In Vivo team and leading its exploratory immunology efforts.